MatchMedi
한국어

Treatment history

Leukemia treatment development timeline

Discoveries and approvals show how the field changed. They do not decide which treatment fits a person, whether someone is eligible, or what order is right.

Important caution

Older does not mean bad, and newer does not mean right. Diagnosis, stage or phase, biomarkers, prior treatment, and country-specific access change the conversation.

At a glance

How the treatment language changed

This diagram shows the broad arc, not an order of treatment or a ranking.

1Transplant

Curative-intent path in selected high-risk settings

2CML targeted pills

Turned BCR-ABL into a long-term control language

3Molecular response

Made supervised treatment-free remission research possible

4Cell therapy

CAR T entered selected ALL contexts

How to read this

Newer tools do not automatically fit every person. Diagnosis, phase or stage, test results, prior treatment, and country access come first.

  1. transplant

    1950s-1970s: Bone marrow and stem cell transplant becomes a curative-intent leukemia strategy

    Doctors learned to rebuild blood-forming cells after intensive treatment using donor or patient stem cells.

    What changed

    For some leukemias, transplant created a possible curative-intent path, especially when relapse risk is high.

    Do not infer

    Transplant is not automatically better than medicine. It carries major risks and depends on subtype, phase, response, donor, age, health, and center experience.

    allogeneic-stem-cell-transplant-curative-risk

    Sources with the medical details

    1. Stem Cell and Bone Marrow Transplants for Cancer. Accessed 2026-05-21.
  2. differentiation therapy

    1988-2000s: APL shifts with differentiation therapy and arsenic trioxide

    Acute promyelocytic leukemia became a model for treating a leukemia by pushing abnormal cells to mature rather than only killing dividing cells.

    What changed

    ATRA and arsenic trioxide transformed APL from one of the most dangerous acute leukemias into a highly treatable subtype when recognized and managed urgently.

    Do not infer

    APL is a special AML subtype. Its treatment logic should not be generalized to all AML, ALL, CLL, or CML.

    aml-source-map

    Sources with the medical details

    1. NCI: Arsenic Trioxide. Accessed 2026-05-21.
    2. Adult Acute Myeloid Leukemia Treatment (PDQ) - Patient Version. Accessed 2026-05-21.
  3. targeted therapy

    2001: Imatinib / Gleevec changes CML

    A pill targeting BCR-ABL became a defining treatment for chronic myeloid leukemia.

    What changed

    CML became a flagship example of long-term cancer control with a targeted medicine for many patients.

    Do not infer

    Stable CML on TKI is not the same as being automatically cured, and medicine should not be stopped without the leukemia team.

    cml-bcr-abl-source-mapcml-tki-long-term-control

    Sources with the medical details

    1. FDA: Information on Gleevec (Imatinib Mesylate). Accessed 2026-05-21.
    2. Chronic Myeloid Leukemia Treatment (PDQ) - Patient Version. Accessed 2026-05-21.
    3. Chronic Myeloid Leukemia Treatment (PDQ) - Health Professional Version. Accessed 2026-05-21.
  4. research

    2010s: Treatment-free remission becomes a supervised CML research goal

    Some carefully selected CML patients with deep, stable molecular responses began studying whether they could stop TKI under close monitoring.

    What changed

    The conversation expanded from lifelong control to supervised treatment-free remission for a subset of patients.

    Do not infer

    This is not self-stopping medicine. It requires exact response history and close molecular monitoring.

    cml-treatment-free-remission-discussion

    Sources with the medical details

    1. Discontinuing Nilotinib in Patients with CML. Accessed 2026-05-21.
    2. NCI-2021-01754: Tyrosine Kinase Inhibitor Cessation for CML Patients With Stable Molecular Response. Accessed 2026-05-21.
  5. chemotherapy

    2017: Vyxeos approved for certain poor-prognosis AML types

    A liposomal chemotherapy combination was approved for adults with therapy-related AML or AML with myelodysplasia-related changes.

    What changed

    AML treatment became more subtype-defined rather than one generic acute leukemia conversation.

    Do not infer

    This does not apply to every AML patient and does not replace subtype, age, fitness, mutation, and transplant discussions.

    aml-source-map

    Sources with the medical details

    1. FDA approves first treatment for certain types of poor-prognosis acute myeloid leukemia. Accessed 2026-05-21.
    2. Adult Acute Myeloid Leukemia Treatment (PDQ) - Patient Version. Accessed 2026-05-21.
  6. cell therapy

    2017: First CAR T-cell therapy approved for B-cell ALL context

    A patient's own T cells could be genetically modified and returned to attack leukemia cells in a specific relapsed/refractory ALL setting.

    What changed

    CAR T-cell therapy became a real leukemia option in selected settings, not just a research concept.

    Do not infer

    CAR T is not for every leukemia, and it has specialized eligibility, center, toxicity, and follow-up requirements.

    all-source-map

    Sources with the medical details

    1. FDA: KYMRIAH / tisagenlecleucel approval information. Accessed 2026-05-21.
    2. NCI: Tisagenlecleucel. Accessed 2026-05-21.
    3. Childhood Acute Lymphoblastic Leukemia Treatment (PDQ) - Patient Version. Accessed 2026-05-21.